Detalles de la búsqueda
1.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 389(21): 1935-1948, 2023 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37937763
2.
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
Cancer Sci
; 115(2): 540-554, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38098261
3.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Cancer Sci
; 114(8): 3330-3341, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37183528
4.
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Int J Clin Oncol
; 28(1): 79-88, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36414827
5.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Int J Clin Oncol
; 28(10): 1354-1368, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37548831
6.
Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).
Cancer Sci
; 113(12): 4327-4338, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36062851
7.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet
; 398(10308): 1344-1357, 2021 10 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34555333
8.
Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Oncologist
; 27(5): e410-e419, 2022 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35348766
9.
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
BMC Cancer
; 22(1): 964, 2022 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36076179
10.
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
Int J Clin Oncol
; 27(12): 1828-1838, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36036294
11.
Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
Cancer Sci
; 112(4): 1556-1566, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33506571
12.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Cancer Sci
; 112(12): 5000-5010, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34543477
13.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2040-2051, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280635
14.
A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
BMC Cancer
; 21(1): 208, 2021 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33648453
15.
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
Int J Clin Oncol
; 26(3): 515-522, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33184754
16.
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Cancer Sci
; 111(12): 4480-4489, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32926507
17.
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
Oncologist
; 25(10): e1451-e1456, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32559335
18.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Oncologist
; 25(3): e536-e544, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162801
19.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1189, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32347358
20.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1177-1187, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140762